Antibodies have become a cornerstone of modern research and in vitro diagnostics, generating yearly revenues close to 2 billion dollars. Most of these are produced in mice, despite some significant intrinsic limitations of mouse antibodies. Belgian spin-off company SynAbs now presents a highly interesting alternative: rat antibodies. By shifting from mouse antibodies to rat antibodies, many new advantages can be exploited to make antibody technology even better.

https://www.synabs.be/2016/01/28/synabs-brings-rats-to-antibody-market/

MEDIA CONTACT
Register for reporter access to contact details